JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maenaka, K.
Right arrow Articles by van der Merwe, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maenaka, K.
Right arrow Articles by van der Merwe, P. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 40, 28329-28334, October 1, 1999


Killer Cell Immunoglobulin Receptors and T Cell Receptors Bind Peptide-Major Histocompatibility Complex Class I with Distinct Thermodynamic and Kinetic Properties*

Katsumi MaenakaDagger §, Takeo Juji§, Takahiro Nakayama§, Jessica R. Wyerparallel , George F. Gaoparallel , Taeko MaenakaDagger , Nathan R. ZaccaiDagger , Akiko Kikuchi§, Toshio Yabe§, Katsushi Tokunaga§, Kenji Tadokoro§, David I. StuartDagger **Dagger Dagger , E. Yvonne JonesDagger **§§, and P. Anton van der MerweDagger Dagger ¶¶

From the Dagger  Structural Biology, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Headington, Oxford OX3 7BN, United Kingdom, § Japanese Red Cross Central Blood Center, 4-3-1 Hiro-o, Shibuya-ku, Tokyo 120, Japan, parallel  MRC Human Immunology Unit, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, the ** Oxford Center for Molecular Sciences, New Chemistry Building, South Parks Road, Oxford OX1 3QT, and the ¶¶ Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human natural killer cells and a subset of T cells express a repertoire of killer cell immunoglobulin receptors (KIRs) that recognize major histocompatibility complex (MHC) class I molecules. KIRs and T cell receptors (TCRs) bind in a peptide-dependent manner to overlapping regions of peptide-MHC class I complexes. KIRs with two immunoglobulin domains (KIR2Ds) recognize distinct subsets of HLA-C alleles. Here we use surface plasmon resonance to study the binding of soluble forms of KIR2DL1 and KIR2DL3 to several peptide-HLA-Cw7 complexes. KIR2DL3 bound to the HLA-Cw7 allele presenting the peptide RYRPGTVAL with a 1:1 stoichiometry and an affinity (Kd ~7 µM at 25 °C) within the range of values measured for other cell-cell recognition molecules, including the TCR. Although KIR2DL1 is reported not to recognize the HLA-Cw7 allele in functional assays, it bound RYRPGTVAL/HLA-Cw7, albeit with a 10-20-fold lower affinity. TCR/peptide-MHC interactions are characterized by comparatively slow kinetics and unfavorable entropic changes (Willcox, B. E., Gao, G. F., Wyer, J. R., Ladbury, J. E., Bell, J. I., Jakobsen, B. K., and van der Merwe, P. A. (1999) Immunity 10, 357-365), suggesting that binding is accompanied by conformational adjustments. In contrast, we show that KIR2DL3 binds RYRPGTVAL/HLA-Cw7 with fast kinetics and a favorable binding entropy, consistent with rigid body association. These results indicate that KIR/peptide-MHC class I interactions have properties typical of other cell-cell recognition molecules, and they highlight the unusual nature of TCR/peptide-MHC recognition.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NK1 cells and CD8 T lymphocytes have complementary roles in the cellular immune response. Whereas CD8 lymphocytes kill cells presenting non-self peptides on MHC class I molecules, NK cells kill cells deficient in MHC class I molecules (1-3). In so doing they make it difficult for intracellular pathogens to evade the immune response by interfering with the expression of MHC class I molecules. It is thought that NK cells are stimulated to kill somatic cells by ligation of one or more activatory receptors but are held in check if inhibitory receptors are able to bind MHC class I molecules on these cells. In humans a family of killer cell Ig receptors (KIRs) has been identified on NK cells, and a subset of T cells, that bind to MHC class I molecules (4). The KIR genes are clustered on chromosome 19q13.4 (5, 6). The precise number (~10) appears to vary between individuals (7). These characteristics, and the absence of homologous genes in rodents, suggest that the KIR gene family evolved fairly recently, perhaps driven by the rapid evolution of MHC class I molecules (8).

KIRs have either two (KIR2D) or three (KIR3D) Ig domains in the extracellular region (9). They can be further grouped according to whether they have a short (e.g. KIR2DS) or long (e.g. KIR2DL) cytoplasmic tail (9). The long cytoplasmic tails contain immunoreceptor tyrosine-based inhibitory motifs and transduce inhibitory signals (10). In contrast, the short cytoplasmic tails mediate association with DAP12 (11), which contains immunoreceptor tyrosine-based activation motifs and transduces activatory signals.

The KIR2D receptors bind HLA-C alleles, whereas KIR3D receptors bind HLA-A and -B alleles (12, 13). Like the TCR, KIRs bind to the peptide-presenting platform on MHC class I molecules (14, 15). The KIR2D-binding site on HLA-C includes residues in the carboxyl-terminal half of the alpha 1-helix (residues 73, 76 and 80) and the adjacent beta -sheet (residue 90). KIR2DL1 binds preferentially to group 1 HLA-C alleles (Cw2, Cw4, Cw5, Cw6, Cw15), which have Lys at position 80, whereas KIR2DL2 and KIR2DL3 bind preferentially to group 2 HLA-C alleles (Cw1, Cw3, Cw7, Cw8), which have Asn at position 80. However, there appears to be some cross-reactivity between these groups (16-18). KIR recognition of peptide-MHC class I has been shown to depend to some extent on the peptide presented on the MHC molecule (17, 19-22). These observations suggest that a single KIR will bind different peptide-MHC complexes with different affinities, raising the question as to what the affinity and/or kinetic threshold is for functional recognition?

Recently Valés-Gómez et al. (23, 24) used surface plasmon resonance to measure the affinity of KIR2DL1 and KIR2DL3 binding HLA-Cw6-peptide and HLA-Cw7-peptide complexes, respectively. The dissociation rate constant (koff) was also estimated, but the association rate constant (kon) could not be measured directly (23, 24). We extend this study by providing more precise kinetic measurements of the KIR2DL3/peptide-HLA-Cw7 interaction, obtaining thermodynamic data, and determining the stoichiometry of the interaction. We also use affinity measurements to quantitate the effects of the peptide on the binding affinity and the degree of cross-reactivity between KIR2DL1 and HLA-Cw7. We find that KIR2DL3 binds peptide-HLA-Cw7 with a 1:1 stoichiometry and with thermodynamic and kinetic properties very similar to other cell-cell recognition molecules. These properties differ from those reported for TCR/peptide-MHC interactions, underlining the unusual nature of TCR recognition.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Production of Soluble Forms of KIR2DL1 and KIR2DL3-- DNA encoding the extracellular portions (residues 1-224) of KIR2DL1 and KIR2DL3 were amplified from cDNA, obtained as described previously (6), using 5'-G GCC ATG GCA CAT GAG GGA GTC CAC-3' as forward primer and 5'-C AGC GGC CGC GTG CAG GTG TCG GGG GTT ACC-3' as reverse primer. The resultant fragments were digested with the restriction enzymes NcoI and NotI and ligated into a derivative of pGEM2 (Promega). The final construct encodes, in tandem, the Shine-Dalgano and signal peptide sequence of pelB, the extracellular portion of KIR2DL1 or KIR2DL3, a c-myc epitope and an oligohistidine tag (HHHHHH), all between the HindIII and EcoRI restriction sites of pGEM2 and under the control of a T7 promoter. The resulting expression plasmid was designated pKMATHNK1 or -2. Escherichia coli strain BL21(DE3)pLysS cells (Novagen) harboring pKMATHNK1 or -2 were grown at 37 °C in 2× YT medium containing ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml), induced with 0.1 mM isopropyl-beta -D-thiogalactopyranoside in logarithmic phase (A280 0.6-0.8), and then incubated for 17 h at 27 °C. Recombinant protein secreted into the periplasmic space and media (yield approximately 0.2 mg/l) were concentrated by ammonium sulfate precipitation and purified by metal-chelate affinity chromatography (Ni-NTA superflow, Qiagen) followed by ion exchange chromatography (MonoQ, Amersham Pharmacia Biotech).

A second expression system was established to increase the yield of KIR2Ds. The genes of the extracellular portions (residues 1-224) of KIR2DL1 and KIR2DL3 were amplified using 5'-GGAACATATGCACGAGGGAG TCCACAG-3' as forward primer and 5'-CGGAGGCTTACTAATGC AGGTGTCTGGGGTTAC-3' as reverse primer. The resultant fragments were digested with the restriction enzymes NdeI and HindIII and ligated into pGMT7 (25), creating the plasmids pGMNK1 and pGMNK2 encoding KIR2DL1 and KIR2DL3, respectively. The plasmids were expressed in the E. coli strain BL21(DE3) pLysS. Recombinant proteins, which accumulate as insoluble aggregates in inclusion bodies, were refolded and purified by the method of Reid et al. (25). In some cases proteins were further purified by ion exchange chromatography (ResourceQ, Amersham Pharmacia Biotech).

Production of Soluble HLA Molecules-- A DNA fragment encoding the extracellular portion of HLA-Cw0702 heavy chain (residues 1-276) was amplified from cDNA kindly provided by Dr. H. Wang, using 5'-CCCACACATATGGGATCCCACTCCATG AGGTATTTCGAC-3' as forward primer and 5'-CCCACAAAGCTTCTATCATGGCTCCCAGCTCAGGGTGAGGGG-3' as reverse primer. The resultant fragment was digested with the restriction enzymes NdeI and HindIII and ligated into pGMT7 (25). HLA-Cw7 was recovered from inclusion bodies, refolded with peptide and beta 2-microglobulin, and purified using the method of Reid et al. (25). One of the following peptides was used: KYFDEHYEY (DS-10), RYRPGTVAL (DS11), or NKADVILKY (DS12). Biotinylated HLA-Cw7 was prepared by refolding in the presence of biotinylated beta 2-microglobulin (26, 27). HLA-A2 (with peptide ILKEPVHGV), HLA-B35 (TPEGIIPTL), HLA-E (VMAPRTVLL), and HLA-G1 (RIIPRHLQL) were produced in the same way.

Surface Plasmon Resonance-- Surface plasmon resonance experiments were performed using a BIAcoreTM 2000 (BIAcore AB, St. Albans, UK). All the experiments were performed at 25 °C unless otherwise indicated using HBS-EP (10 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, and 0.005% Surfactant P20) as running buffer when using CM5 sensor chips and HBS-P (HBS-EP without EDTA) when using Ni-NTA sensor chips (BIAcore AB). Biotinylated proteins were immobilized via streptavidin, which was covalently coupled to CM5 research grade sensor chips as described previously (28). Proteins with oligohistidine tags (sKIR2DL3H and sKIR2DL1H) were immobilized onto Ni-NTA sensor chips (BIAcore AB). Ni-NTA surfaces were regenerated by injection of 0.35 M EDTA (pH 8.3) for 1 min to elute bound protein followed by 0.5 M NiCl2 for 1 min to recharge the NTA with nickel.

Kinetic constants were derived using the curve-fitting facility of the BIAevaluation program (version 3.0, BIAcore) that deploys the Marquardt-Levenberg algorithm. Rate equations were derived from the simple 1:1 Langmuir binding model (A + B left-right-arrow  AB). Other curve fitting was performed in Origin version 3 (MicroCal). Affinity constants were derived by Scatchard analysis or by non-linear curve fitting of the standard Langmuir binding isotherm. Thermodynamic data were obtained by fitting to the data in Fig. 4A the non-linear form of the van't Hoff Equation (29),
&Dgr;G<SUP>0</SUP>=&Dgr;H<SUB>To</SUB>−T · &Dgr;S<SUP>0</SUP><SUB>To</SUB>+&Dgr;C<SUB>p</SUB>(T−To)+T · &Dgr;C<SUB>p</SUB> · <UP>ln</UP><FENCE><FR><NU>T</NU><DE>T<SUB>o</SUB></DE></FR></FENCE> (Eq. 1)
where T is the temperature in Kelvin (K); To is an arbitrary reference temperature (e.g. 298.15 K); Delta G0 is the standard free energy of binding at T (kcal·mol-1) and is calculated from the Kd; Delta HTo is the enthalpy change upon binding at To (kcal·mol-1); Delta S0To is the standard state entropy change upon binding at To (kcal·mol-1), and Delta Cp is the specific heat capacity (kcal·mol-1·K-1), and is assumed to be temperature-independent.

Gel Filtration-- sKIR2DL3 (60 µl at 1 mM) and HLA-Cw7-DS11 (40 µl at 1 mM) were mixed and incubated for 1 h at room temperature before separation by fast protein liquid chromatography on a Superdex 200 (Amersham Pharmacia Biotech) in 20 mM Tris-Cl (pH 8) at a flow rate of 0.4 ml/min.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Stoichiometry and Peptide Dependence of sKIR2DL3 Binding to HLA-Cw7-- Soluble MHC class I heavy chains were expressed in bacteria and refolded in vitro together with peptide and beta 2-microglobulin (see "Experimental Procedures"). Biotinylated peptide-MHC class I complexes were produced by refolding with chemically biotinylated beta 2-microglobulin (28). Soluble forms of KIR2D molecules were also expressed in bacteria, either with (sKIR2DL1H and sKIR2DL3H) or without (sKIR2DL1 and sKIR2DL3) carboxyl-terminal c-myc and oligohistidine tags (see "Experimental Procedures"). sKIR2DL3H was used successfully for an x-ray crystallographic structure determination (30), indicating that it is correctly folded. Purified sKIRs migrated as monomers on size exclusion chromatography (Fig. 1B and data not shown).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Peptide dependence and stoichiometry of sKIR2DL3 binding to HLA-Cw7. A, sKIR2DL3 (106 µM) was injected at a flow rate of 10 µl/min (solid bar) through flow cells with the indicated peptide-MHC class I complex immobilized to the sensor surface. HLA-Cw7 was complexed with DS10, DS11, or DS12 peptides (see "Experimental Procedures"). B, size exclusion chromatography of sKIR2DL3/HLA-Cw7-DS11 complex. A 100-µl mixture of sKIR2DL3 (0.6 mM) and HLA-Cw7-DS11 (0.4 mM) was fractionated on a Sephadex 200 column. The elution positions are shown of protein molecular mass standards (in kDa). A calibration curve based on these standards was used to estimate the Mr of sKIR2DL3 and the sKIR2DL3-HLA-Cw7-DS11 complex. Also shown is the expected elution position of free HLA-Cw7-DS11, which was determined on a separate run (data not shown). RU, response units.

Binding of KIR constructs was analyzed by surface plasmon resonance, which measures the changes in refractive index near a sensor surface (31). sKIR2DL3 was injected through 4 flow cells containing sensor surfaces to which different peptide-MHC class I complexes had been immobilized using their biotin tag (Fig. 1A, solid bar). A "background" response (measured in response units) is seen in the negative control HLA-A2 flow cell, a consequence of the high concentration, and therefore high refractive index, of injected sKIR2DL3 sample. However, a greater response is seen with injection over HLA-Cw7 complexed with the DS11 peptide, indicating binding (Fig. 1A). sKIR2DL3 bound at a much lower level to HLA-Cw7 complexed with the DS12 peptide and did not bind at all to the HLA-Cw7-DS10 complex (Fig. 1A).

In order to assess the stoichiometry of binding, HLA-Cw7-DS11 and sKIR2DL3 were mixed together, with a molar excess of sKIR2DL3 (1:1.5), and then fractionated by size exclusion chromatography (Fig. 1B). The elution position of the complex (~74 kDa, calculated Mr 69,304) is consistent with the presence of one sKIR2DL3 molecule and one HLA-Cw7-DS11 molecule. Furthermore, whereas free sKIR2DL3 was present, no free HLA-Cw7-DS11 was detected, indicating that there was an excess of the sKIR2DL3 (Fig. 1B). Taken together, these data indicate that sKIR2DL3 binds HLA-Cw7-DS11 with a 1:1 stoichiometry.

Affinity of sKIR2DL3 and sKIR2DL1 Binding to HLA-Cw7 Peptide-- The affinity of sKIR2Ds binding to peptide-MHC molecules was measured by equilibrium binding analysis on the BIAcore. A range of concentrations of sKIR2DL3 (Fig. 2A) was injected through flow cells with HLA-Cw7-DS11 or a control peptide-MHC class I complex immobilized. The binding response at each concentration was calculated by subtracting the equilibrium response measured in the control flow cell from response in the HLA-Cw7-DS11 flow cell. Conventional (Fig. 2B) and Scatchard (Fig. 2B, inset) plots of these binding data indicate that the interaction conforms to a simple 1:1 (Langmuir) binding model with a Kd of ~9 µM. The results of several experiments are summarized in Table I. Other soluble recombinant forms of sKIR2DL3 bound immobilized HLA-Cw7-DS11 with a similar affinity (data not shown). These included sKIR2DL3H and a truncated version of sKIR2DL3 (comprising amino acids 1-200) which lacked the membrane-proximal stalk region. A similar affinity was measured in the reverse orientation, with sKIR2DL3H immobilized to a Ni2+-NTA sensor chip via its oligohistidine tag, and HLA-Cw7-DS11 in solution (Table I).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 2.   Affinity of KIR molecules binding to immobilized HLA-Cw7-DS11. A, sKIR2DL3 was injected for 30 s at the indicated concentrations through flow cells with HLA-Cw7. B, a plot of the equilibrium binding response of sKIR2DL3 (, derived from A) and sKIR2DL1 (black-triangle, raw data not shown) versus concentration. The solid lines represent direct non-linear fits of the 1:1 Langmuir binding isotherm to the data, which yielded the indicated Kd values. Inset, Scatchard plots of the same data are shown. The solid lines are linear fits, which yielded Kd estimates of 8 and 84 µM for sKIR2DL3 and sKIR2DL1, respectively. RU, response units.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Summary of affinity constants

The weak interaction between sKIR2DL3 and HLA-Cw7-DS12 peptide (Fig. 1A) was confirmed by affinity analysis (data not shown). sKIR2DL3 bound to HLA-Cw7-DS12 with an affinity (Kd ~108 µM) ~12-fold lower than its affinity for HLA-Cw7-DS11 (Fig. 2B). This very low affinity was confirmed in the reverse orientation, with sKIR2DL3H immobilized and HLA-Cw7/DS12 in solution.

sKIR2DL1 also bound to HLA-Cw7-DS11, albeit with a 10-15-fold lower affinity than sKIR2DL3 (Fig. 2B and Table I). This lower affinity was largely a consequence of a faster koff (data not shown), indicating that it is not a consequence of low sKIR2DL1 activity. No binding was detected when high concentrations (up to 3 mM) of sKIR2DL1 and sKIR2DL3 were injected over several other classical (HLA-A2 and -B35) and non-classical (HLA-E and -G1) MHC class I molecules (Table I).

Binding Kinetics-- Although binding and dissociation were very fast, it was possible to analyze both the association and dissociation phases of binding (Fig. 3). Global fitting with mono-exponential rate equations derived from the simple 1:1 Langmuir binding model produced reasonable fits, yielding a kon of 1.6 × 105 M-1 s-1 and a koff of 1.2 s-1 (Fig. 3A). The rate constants did not change significantly when the level of immobilized HLA-Cw7-DS11 varied 2-fold (Table II), indicating that binding was not substantially affected by mass transport or rebinding artifacts. The excellent agreement between calculated Kd (Table II) and the Kd determined by equilibrium binding (Table I) further supports the notion that these kinetic constants are correct.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   Kinetic analysis of sKIR2DL3 binding to HLA-Cw7-DS11. A, sKIR2DL3 was injected (solid bar) at the indicated concentrations at high flow rate (50 µl·min-1) over HLA-C7-DS11 (1500 response units (RU)). The traces shown have had their corresponding background responses (obtained with injection over the HLA-A2 surface) subtracted. Rate equations derived from the 1:1 Langmuir binding model (A + B left-right-arrow  AB) were fitted by numerical integration simultaneously to the association and dissociation phases of all three injections ("global fitting"). Residual errors from the fits are shown in the bottom panel. B, temperature dependence of binding kinetics. sKIR2DL3 (10 µM) was injected (solid bar) at 50 µl·min-1 over HLA-Cw7-DS11 at the indicated temperatures. The responses observed with injection of the same samples over HLA-A2-peptide have been subtracted. To aid comparison the traces have been normalized so that maximum binding at each temperature equals 100%. The koff values, determined by fitting mono-exponential decay curves (solid lines), were 0.2, 0.34, and 0.8 s-1 at 5, 15, and 25 °C, respectively. Inset, Arrhenius plot of koff data (KIR). Also shown is an Arrhenius plot of the koff of the JM22z TCR dissociating from HLA-A2-Flu peptide, taken from Ref. 32.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Summary of kinetic data

Because recent studies have shown that the kinetics of TCR binding to peptide-MHC are strongly temperature-dependent (32), we analyzed the temperature dependence of the KIR/peptide-MHC interaction (Fig. 3B). The koff of a TCR/peptide-MHC interaction increased ~40-fold as the temperature was raised from 5 to 25 °C (32). In contrast, the koff of the sKIR2DL3/HLA-Cw7-DS11 interaction increased a modest ~4-fold over the same temperature range (Fig. 3B). Arrhenius plots yield an activation energy of 13 kcal·mol-1 for sKIR2DL3/HLA-Cw7-DS11 dissociation (Fig. 3B, inset), far lower than the ~30 kcal·mol measured for TCR/peptide-MHC dissociation (32).

Thermodynamic Analysis-- The enthalpy change (Delta H) that accompanies KIR binding to peptide-MHC was estimated by van't Hoff analysis, which involves measuring the dependence of affinity on temperature (Fig. 4A). Because the enthalpy and entropy vary with temperature, the non-linear form of the van't Hoff equation was used (see "Experimental Procedures"). At 25 °C favorable enthalpic (Delta HvH ~ -4.1 kcal·M-1) and entropic (-TDelta S0 ~ -3.1 kcal·M-1) changes contribute in approximately equal measure to the binding energy (Delta G0 ~ -7.2 kcal·M-1). The heat capacity derived from this fit (Delta Cp ~ -100 cal·M-1), which is a measure of the dependence of the binding enthalpy and entropy change on temperature, is well within the range determined for other protein/protein interactions (33). Similar values for Delta HvH and -TDelta S0 were obtained when using the linear form of van't Hoff equation (data not shown), which assumes that the enthalpy is temperature-independent.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   A, thermodynamic analysis of sKIR2DL3 binding to HLA-Cw7-DS11. Measurement of enthalpy by van't Hoff analysis (Delta HvH). Affinity constants for the sKIR2DL3/HLA-Cw7-DS11 interaction were measured at several temperatures (5-30 °C) and converted into the standard free energy of binding (Delta G0). Values for the enthalpic (Delta HvH) and standard entropic (-TDelta S0) changes (at 25 °C) and the specific heat capacity (Delta Cp) were derived by fitting the non-linear form of the van't Hoff equation to these data (see "Experimental Procedures"). B, comparison of thermodynamic properties (at 25 °C) of several macromolecular interactions. The values for protein/protein interactions (excluding antibody/protein interactions) are the mean and S.E. of 30 calorimetric determinations taken from Ref. 33. Data for TCR/peptide-MHC interactions are the mean and range of two determinations, one of which was by calorimetry (32).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Peptide Dependence-- Although several studies have demonstrated that NK cell recognition is dependent on the peptide as well as the MHC on target cells, no studies have measured directly the effect of peptide on the affinity of a KIR for a peptide-MHC class I complex. Consistent with functional (21) and binding (18) assays, we found that the affinity of sKIR2DL3 binding to HLA-Cw7-peptide was dramatically affected by the nature of the peptide (Fig. 1A and Table I). sKIR2DL3 bound to HLA-Cw7-DS11, -DS12, and -DS10 with a Kd ~7 µM, ~115 µM, and >3 mM, respectively (Table I). In agreement with this, Valés-Gómez et al. (18) found that sKIR2DL3 bound to HLA-Cw7-DS11 but not to HLA-Cw7-DS10. Interestingly, Mandelboim et al. (21) showed that killing by several NK clones specific for group 2 HLA-C alleles was inhibited when target cells expressed HLA-Cw7 loaded with the DS12 peptide. This suggests that affinities as low as Kd ~115 µM are sufficient to mediate inhibition. Paradoxically, however, HLA-Cw7-loaded with DS10 peptide (KYFDEHYEY), which we and others (18) show does not bind to sKIR3DL3, was a better inhibitor of most of these NK clones than HLA-Cw7-DS12 (21). In only one of the clones studied (dp10.7) did the functional inhibition data (21) correlate with the direct binding data. A likely explanation for these results is that these NK clones express multiple KIRs, highlighting the importance of using purified KIRs to analyze the binding specificity.

Stoichiometry-- Based on the structural similarity between KIR2DL1 and hematopoietic receptors (e.g. growth hormone receptor, which binds growth hormone with a 2:1 stoichiometry), Fan et al. (34) proposed that a single peptide-MHC class I complex might bind to two KIR molecules, providing a possible mechanism for signaling. However, our results suggest that sKIR2DL3 binds to soluble HLA-Cw7-DS11 in a 1:1 complex. First, free sKIR2DL3 but no free HLA-Cw7-DS11 is detected when sKIR2DL3 and HLA-Cw7-DS11 are mixed in a ratio 1.5:1. Second, the sKIR2DL3/HLA-Cw7-DS11 complex migrated on gel filtration at the position expected for a 1:1 complex. Third, SDS-polyacrylamide gel electrophoresis of the peak complex indicated that there were equimolar amounts of sKIR2DL3 and HLA-Cw7 heavy chain (data not shown). Finally, the standard Langmuir 1:1 binding model fits very well to the equilibrium binding and kinetic data. We cannot exclude a second sKIR2DL3 site on HLA-Cw7 with a much lower affinity (e.g. Kd >200 µM). However, such a second site would need to achieve a much higher "physiological" affinity at the cell/cell interface in order to contribute to KIR2DL3 binding (35).

The 1:1 binding stoichiometry suggests that, despite some structural similarities between KIRs and hematopoietic receptors, they do not bind their ligands in the equivalent manner. Indeed, comparison of the recently determined KIR2DL3 crystal structure with Ig superfamily and fibronectin type III domains indicates that KIRs bear a closer resemblance to Ig domains than to the fibronectin type III domains of hematopoietic receptors (30).

Affinity, Kinetics, and Thermodynamics-- The affinity measured here between soluble forms of KIR2DL3 and the HLA-Cw7-DS11 peptide-MHC complex agrees well with the affinity measured independently by Valés-Gómez et al. (24) (Kd ~9 µM) for sKIR2DL3 binding HLA-Cw7-DS11. Valés-Gómez et al. (24) measured a similar affinity (Kd ~10 µM) between soluble forms of sKIR2DL1 and HLA-Cw6-peptide. This consistency between completely independent studies suggests that these affinity measurements are likely to be correct.

These affinities are well within the range of affinities measured for many other cell-cell recognition molecules, including TCR/peptide-MHC interactions (Table III). However TCR/peptide-MHC interactions differ from other cell-cell molecule interactions in that low affinity of TCR binding is a consequence of a relatively slow kon rather than a fast koff (32, 36). Unlike Valés-Gómez et al. (23, 24), we were able to obtain precise estimates of the binding kinetics of the sKIR2DL3/HLA-Cw7-DS11 interaction. This revealed that, in contrast to TCR/peptide-MHC interactions, the low affinity is a consequence of a faster koff, whereas the kon is unremarkable, being typical of other cell surface protein/protein interactions (Table III). Furthermore, the KIR binding kinetics did not show the strong temperature dependence observed with TCR binding.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Summary of affinity and kinetic data for lymphocyte cell-cell recognition molecules

Further differences between KIR/peptide-MHC and TCR/peptide-MHC interactions were evident in thermodynamic studies. Unlike TCR binding, which is characterized by large, unfavorable entropic changes compensated for by even larger favorable enthalpic changes, KIR binding is driven by favorable entropic and enthalpic changes at 25 °C (Fig. 4B). The latter thermodynamic characteristics are typical of protein/protein interactions (Fig. 4B) including low affinity interactions between cell-cell recognition molecules, such as the CD2/CD48 interaction.2

A key finding in this study is that TCRs and KIRs, although recognizing overlapping portions of peptide-MHC class I molecules, bind with very different kinetic and thermodynamic properties. The KIR/peptide-MHC interaction has binding properties consistent with rigid body association, whereas TCR binding has been shown to require conformational adjustments (37) and is likely to be accompanied by a reduction in conformational flexibility (32). The difference in the binding properties of KIRs and TCRs for very similar ligands supports the suggestion the TCR and not the peptide-MHC are the primary source of conformational flexibility. We have proposed that these binding properties arise from the structure of TCR antigen-binding sites and the unique manner in which they are generated (32). First, these antigen-binding sites are formed from peptide loops exclusively, 3-4 from each of the two V domains. Second, the loops have highly variable primary structures and are combined in a semi-random manner. Third, because TCR antigen-binding sites are not germline-encoded and cannot be inherited, they are denied the opportunity, available to other ligand-binding proteins, to acquire a more stable tertiary structure during the course of evolution.

Cross-reactivity of KIR2DL1 with HLA-Cw7-- Although KIR2DL molecules are grouped according to whether they bind to group 1 (KIR2DL1) or group 2 (KIR2DL2 and -L3) HLA-C alleles, recent data suggest that there is some cross-reactivity. KIR2DL2 and -L3 have been shown to bind to, and mediate inhibition by, group 1 HLA-C alleles. We show here that KIR2DL1 can also cross-react with a group 2 HLA-C allele. The affinity of the latter interaction is ~10-fold lower than the affinity of sKIR2DL1 and sKIR2DL2 or 3 molecules for group 1 and group 2 HLA-C alleles, respectively. Interestingly, Valés-Gómes et al. (18) also found some evidence for weak binding of sKIR2DL1 and HLA-Cw7-peptide. Whether such cross-reactivity is functionally significant remains to be demonstrated.

Conclusion-- We show here that a KIR binds peptide-MHC with a 1:1 stoichiometry and that the thermodynamic and kinetic features of this interaction are typical of cell/cell recognition molecules and consistent with rigid body association. This contrasts with TCR/peptide-MHC interactions, which have thermodynamic and kinetic properties more consistent with conformational adjustments at the binding interface. These differences draw attention to some unusual features of antigen recognition by TCRs and suggest that there are fundamental differences in the signal transduction mechanisms that follow KIR and TCR ligation of peptide-MHC.

    ACKNOWLEDGEMENTS

We thank I. Kumagai, M. Matsushima, and K. Tsumoto for their advice and helpful discussion; B. Willcox, C. O'Callaghan, B. Jakobsen, A. McMichael, and J. Bell for MHC class I molecules; and H. Wang for providing a cDNA of HLA-Cw0702. We are grateful to our colleagues in the Japanese Red Cross Blood Center for their encouragement. The Oxford Center for Molecular Sciences is supported by the BBSRC, MRC, and EPSRC.

    FOOTNOTES

* This work was supported in part by a Grant-in-aid for Scientific Research on Priority Areas 2782 from the Ministry of Education, Science, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported in part by a JSPS Research Fellowship for Young Scientists and by a Human Frontier Science Program long term fellowship. To whom correspondence should be addressed: Structural Biology, Wellcome Trust Centre for Human Genetics, Roosevelt Dr., Headington, Oxford OX3 7BN, UK. Tel.: 44-1865-287550; Fax: +44-1865-287547; E-mail: katsumi@strubi.ox.ac.uk.

Dagger Dagger Supported by the MRC.

§§ Supported by the Royal Society. To whom correspondence should be addressed: Structural Biology, Wellcome Trust Centre for Human Genetics, Roosevelt Dr., Headington, Oxford OX3 7BN, UK. Tel.: 44-1865-287559; Fax: 44-1865-287547; E-mail: yvonne@strubi.ox.ac.uk.

2 J. Ladbury, P. A. van der Merwe, and S. J. Davis, unpublished data.

    ABBREVIATIONS

The abbreviations used are: NK, natural killer; KIR, killer cell immunoglobulin receptor; KIR2D, KIR with 2 Ig domains; MHC, major histocompatibility complex; TCR, T cell receptor; Ni-NTA, nickel charged nitrilotriacetic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Karre, K., Ljunggren, H. G., Piontek, G., and Kiessling, R. (1986) Nature 319, 675-678[CrossRef][Medline] [Order article via Infotrieve]
2. Ljunggren, H. G., and Karre, K. (1990) Immunol. Today 11, 237-244[CrossRef][Medline] [Order article via Infotrieve]
3. Liao, N. S., Bix, M., Zijlstra, M., Jaenisch, R., and Raulet, D. (1991) Science 253, 199-202[Abstract/Free Full Text]
4. Lanier, L. L. (1997) Immunity 6, 371-378[CrossRef][Medline] [Order article via Infotrieve]
5. Baker, E., D'Andrea, A., Phillips, J. H., Sutherland, G. R., and Lanier, L. L. (1995) Chromosome Res. 3, 511-512[CrossRef]
6. Suto, Y., Maenaka, K., Yabe, T., Hirai, M., Tokunaga, K., Tadokoro, K., and Juji, T. (1996) Genomics 35, 270-272[CrossRef][Medline] [Order article via Infotrieve]
7. Suto, Y., Ishikawa, Y., Kasahara, M., Kasai, F., Yabe, T., Akaza, T., and Juji, T. (1998) Immunogenetics 48, 235-241[CrossRef][Medline] [Order article via Infotrieve]
8. Gumperz, J. E., and Parham, P. (1995) Nature 378, 245-248[CrossRef][Medline] [Order article via Infotrieve]
9. Selvakumar, A., Steffens, U., Palanisamy, N., Chaganti, R. S., and Dupont, B. (1997) Tissue Antigens 49, 564-573[Medline] [Order article via Infotrieve]
10. Lanier, L. L. (1998) Annu. Rev. Immunol. 16, 359-393[CrossRef][Medline] [Order article via Infotrieve]
11. Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., and Phillips, J. H. (1998) Nature 391, 703-707[CrossRef][Medline] [Order article via Infotrieve]
12. Colonna, M. (1996) Curr. Opin. Immunol. 8, 101-107[CrossRef][Medline] [Order article via Infotrieve]
13. Lanier, L. L., and Phillips, J. H. (1996) Immunol. Today 17, 86-91[CrossRef][Medline] [Order article via Infotrieve]
14. Biassoni, R., Falco, M., Cambiaggi, A., Costa, P., Verdiani, S., Pende, D., Conte, R., Di Donato, C., Parham, P., and Moretta, L. (1995) J. Exp. Med. 182, 605-609[Abstract/Free Full Text]
15. Mandelboim, O., Reyburn, H. T., Sheu, E. G., Valés-Gómez, M., Davis, D. M., Pazmany, L., and Strominger, J. L. (1997) Immunity 6, 341-350[CrossRef][Medline] [Order article via Infotrieve]
16. Winter, C. C., Gumperz, J. E., Parham, P., Long, E. O., and Wagtmann, N. (1998) J. Immunol. 161, 571-577[Abstract/Free Full Text]
17. Kim, J., Chwae, Y. J., Kim, M. Y., Choi, I. H., Park, J. H., and Kim, S. J. (1997) J. Immunol. 159, 3875-3882[Abstract]
18. Valés-Gómez, M., Reyburn, H. T., Erskine, R. A., and Strominger, J. L. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14326-14331[Abstract/Free Full Text]
19. Malnati, M. S., Peruzzi, M., Parker, K. C., Biddison, W. E., Ciccone, E., Moretta, A., and Long, E. O. (1995) Science 267, 1016-1018[Abstract/Free Full Text]
20. Rajagopalan, S., and Long, E. O. (1997) J. Exp. Med. 185, 1523-1528[Abstract/Free Full Text]
21. Mandelboim, O., Wilson, S. B., Valés-Gómez, M., Reyburn, H. T., and Strominger, J. L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4604-4609[Abstract/Free Full Text]
22. Zappacosta, F., Borrego, F., Brooks, A. G., Parker, K. C., and Coligan, J. E. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6313-6318[Abstract/Free Full Text]
23. Valés-Gómez, M., Reyburn, H. T., Mandelboim, M., and Strominger, J. L. (1998) Immunity 9, 337-344[CrossRef][Medline] [Order article via Infotrieve]
24. Valés-Gómez, M., Reyburn, H. T., Mandelboim, M., and Strominger, J. L. (1998) Immunity 9, 892[CrossRef]
25. Reid, S. W., Smith, K. J., Jakobsen, B. K., O'Callaghan, C. A., Reyburn, H., Harlos, K., Stuart, D. I., McMichael, A. J., Bell, J. I., and Jones, E. Y. (1996) FEBS Lett. 383, 119-123[CrossRef][Medline] [Order article via Infotrieve]
26. Garboczi, D. N., Hung, D. T., and Wiley, D. C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3429-3433[Abstract/Free Full Text]
27. Vessey, S. J., Barouch, D. H., McAdam, S. N., Tussey, L. G., Davenport, M. A., O'Callaghan, C. A., Bell, J. I., McMichael, A. J., and Jakobsen, B. K. (1997) Eur. J. Immunol. 27, 879-885[Medline] [Order article via Infotrieve]
28. Wyer, J. R., Willcox, B. E., Gao, G. F., Gerth, U. C., Davis, S. J., Bell, J. I., van der Merwe, P. A., and Jakobsen, B. K. (1999) Immunity 10, 219-225[CrossRef][Medline] [Order article via Infotrieve]
29. Yoo, S. H., and Lewis, M. S. (1995) Biochemistry 34, 632-638[CrossRef][Medline] [Order article via Infotrieve]
30. Maenaka, K., Juji, T., Stuart, D. I., and Jones, E. Y. (1999) Structure 7, 391-398[Medline] [Order article via Infotrieve]
31. Karlsson, R., and Falt, A. (1997) J. Immunol. Methods 200, 121-133[CrossRef][Medline] [Order article via Infotrieve]
32. Willcox, B. E., Gao, G. F., Wyer, J. R., Ladbury, J. E., Bell, J. I., Jakobsen, B. K., and van der Merwe, P. A. (1999) Immunity 10, 357-365[CrossRef][Medline] [Order article via Infotrieve]
33. Stites, W. E. (1997) Chem. Rev. 97, 1233-1250[CrossRef][Medline] [Order article via Infotrieve]
34. Fan, Q. R., Mosyak, L., Winter, C. C., Wagtmann, N., Long, E. O., and Wiley, D. C. (1997) Nature 389, 96-100[CrossRef][Medline] [Order article via Infotrieve]
35. Dustin, M. L., Golan, D. E., Zhu, D. M., Miller, J. M., Meier, W., Davies, E. A., and van der Merwe, P. A. (1997) J. Biol. Chem. 272, 30889-30898[Abstract/Free Full Text]
36. Davis, M. M., Boniface, J. J., Reich, Z., Lyons, D., Hampl, J., Arden, B., and Chien, Y. (1998) Annu. Rev. Immunol. 16, 523-544[CrossRef][Medline] [Order article via Infotrieve]
37. Garcia, K. C., Degano, M., Pease, L. R., Huang, M., Peterson, P. A., Teyton, L., and Wilson, I. A. (1998) Science 279, 1166-1172[Abstract/Free Full Text]
38. van der Merwe, P. A., Barclay, A. N., Mason, D. W., Davies, E. A., Morgan, B. P., Tone, M., Krishnam, A. K. C., Ianelli, C., and Davis, S. J. (1994) Biochemistry 33, 10149-10160[CrossRef][Medline] [Order article via Infotrieve]
39. Davis, S. J., Ikemizu, S., Wild, M. K., and van der Merwe, P. A. (1998) Immunol. Rev. 163, 217-236[CrossRef][Medline] [Order article via Infotrieve]
40. Brown, M. H., Boles, K., van der Merwe, P. A., Kumar, V., Mathew, P. A., and Barclay, A. N. (1998) J. Exp. Med. 188, 2083-2090[Abstract/Free Full Text]
41. van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., and Davis, S. J. (1997) J. Exp. Med. 185, 393-403[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
G. Alter, S. Rihn, H. Streeck, N. Teigen, A. Piechocka-Trocha, K. Moss, K. Cohen, A. Meier, F. Pereyra, B. Walker, et al.
Ligand-Independent Exhaustion of Killer Immunoglobulin-Like Receptor-Positive CD8+ T Cells in Human Immunodeficiency Virus Type 1 Infection
J. Virol., October 1, 2008; 82(19): 9668 - 9677.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS
J. Leukoc. Biol., July 1, 2008; 84(1): 1 - 26.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Tabata, K. Kuroki, J. Wang, M. Kajikawa, I. Shiratori, D. Kohda, H. Arase, and K. Maenaka
Biophysical Characterization of O-Glycosylated CD99 Recognition by Paired Ig-like Type 2 Receptors
J. Biol. Chem., April 4, 2008; 283(14): 8893 - 8901.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. K. Moesta, P. J. Norman, M. Yawata, N. Yawata, M. Gleimer, and P. Parham
Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL3
J. Immunol., March 15, 2008; 180(6): 3969 - 3979.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
T. R. Patel, S. E. Harding, A. Ebringerova, M. Deszczynski, Z. Hromadkova, A. Togola, B. S. Paulsen, G. A. Morris, and A. J. Rowe
Weak Self-Association in a Carbohydrate System
Biophys. J., August 1, 2007; 93(3): 741 - 749.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
R. J. Lebbink, T. de Ruiter, J. Adelmeijer, A. B. Brenkman, J. M. van Helvoort, M. Koch, R. W. Farndale, T. Lisman, A. Sonnenberg, P. J. Lenting, et al.
Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1
J. Exp. Med., June 12, 2006; 203(6): 1419 - 1425.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
S.A. Richman, S.J. Healan, K.S. Weber, D.L. Donermeyer, M.L. Dossett, P.D. Greenberg, P.M. Allen, and D.M. Kranz
Development of a novel strategy for engineering high-affinity proteins by yeast display
Protein Eng. Des. Sel., June 1, 2006; 19(6): 255 - 264.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. J. Boyton, J. Smith, R. Ward, M. Jones, L. Ozerovitch, R. Wilson, M. Rose, J. Trowsdale, and D. M. Altmann
HLA-C and Killer Cell Immunoglobulin-like Receptor Genes in Idiopathic Bronchiectasis
Am. J. Respir. Crit. Care Med., February 1, 2006; 173(3): 327 - 333.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. A. Stewart, F. Laugier-Anfossi, F. Vely, X. Saulquin, J. Riedmuller, A. Tisserant, L. Gauthier, F. Romagne, G. Ferracci, F. A. Arosa, et al.
Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors
PNAS, September 13, 2005; 102(37): 13224 - 13229.
[Abstract] [Full Text] [PDF]